Sign in
Taking people in United StatesPhase 1

Tests DR-0202 in adults with advanced or returning solid tumor cancers

Tests the drug DR-0202 in adults with advanced cancers that have returned or stopped responding.

Key facts

Who runs it
Dren Bio
Where
Austin, Dallas, Denver, Fairfax, Greenville, Huntersville, Oklahoma City, Orlando, San Antonio, and Sarasota, United StatesSee the 10 sites
Trial code
Registry title
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Status
Recruiting
Phase
Phase 1
People taking part
96 people, planned
Started
3 Jun 2025
Expected to end
Dec 2027
Type of study
Interventional, 8 groups
Treatments tested
  • DR-0202
Record updated
7 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic epithelial cancers that came back or did not respond, who have had at least 2 earlier treatments and have no standard options left.

Age
18 years and older
Sex
All sexes can join.
Disease stage
Unresectable, locally advanced or metastatic epithelial cancer (breast, lung (NSCLC), cervical, castrate-resistant prostate, pancreatic, head and neck, endometrial, ovarian, gastric/GEJ or urothelial) that is measurable on scans.
Earlier treatment
Relapsed or refractory after at least 2 prior lines of therapy, with no standard treatment options available. Needs a break from earlier cancer treatments, including 4 weeks without chemotherapy or antibody-based therapy.

Main reasons for not taking part

  • Brain metastases that are untreated and cause symptoms or need steroids or anticonvulsants
  • Another cancer (with some exceptions)
  • Earlier solid organ transplant
  • Uncontrolled or significant heart disease, or heart rhythm test result (QTcF) over 480 msec
  • Active infection needing treatment through a vein, or active interstitial pneumonitis

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Histologically confirmed epithelial cancer of the following tumor types: breast (TNBC, HR+/HER2-/+BC), NSCLC, cervical, CRPC, PDAC, HNSCC, endometrial, ovarian, gastric/GEJ, or urothelial that is unresectable, locally advanced or metastatic
  • Relapsed or refractory with at least 2 prior lines of therapy and for which no standard of care treatment options are available
  • Radiographically measurable disease
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Life expectancy, in the opinion of the Investigator, of ≥ 3 months
  • Adequate marrow reserve, renal function, and hepatic function
  • Taper of ≥ 2 weeks from high-dose systemic corticosteroids (however, low dose corticosteroids ≤ 25 mg prednisone or equivalent daily are permitted in consultation with the Medical Monitor)
  • Willing to provide archival tumor tissue samples or agree to a baseline biopsy if not available
  • Willing to undergo an on-treatment biopsy if clinically feasible and not contraindicated at the time of procedure

Who cannot take part

  • Major surgery within 28 days prior to Day 1
  • Have not had an appropriate washout period from systemic therapy, including investigational agents, prior to C1D1:; Systemic chemotherapy and anticancer therapies within 4 weeks or 5 half-lives of the drug, whichever is shorter; Antibody-based anticancer therapy: ≥ 4 weeks. Note: Treatment with systemic corticosteroids ≤ 25 mg/day (prednisone or equivalent) and inhaled or topical steroids are allowed. For participants with CRPC, LHRH agents are allowed
  • Radiation therapy within 21 days prior to C1D1. Palliative radiation therapy may be allowed following discussion with Medical Monitor
  • Brain metastases either untreated and symptomatic or requiring therapy with steroids or anticonvulsants to control associated symptoms. Brain metastases that have been treated and are no longer symptomatic are allowed if use of high-dose systemic corticosteroids (> 25 mg/day of prednisone or equivalent) is stopped ≥ 12 weeks prior to C1D1
  • Another malignancy (except for adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated with no evidence of disease for ≥ 1 year)
  • Evidence of significant, uncontrolled concomitant disease that could affect compliance with study
  • History or presence of an abnormal ECG that is clinically significant in the Investigator's opinion or myocardial infarction within 6 months prior to C1D1
  • Prior solid organ transplantation
  • Active infection requiring systemic treatment, defined as requiring IV antimicrobial, antifungal, or antiviral agents within 2 weeks prior to C1D1. Prophylactic antimicrobial treatment is allowed. Infections eligible per Exclusion Criterion 16 may be enrolled
  • Active clinical interstitial pneumonitis (e.g., shortness of breath, requirement of supplemental oxygen, dry cough) or as confirmed by means of diagnostic imaging within 6 months prior to C1D1
  • Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations
  • Current or past history of CNS disease, such as stroke, epilepsy, central nervous system vasculitis or neurodegenerative disease (participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 6 months and have no residual neurologic deficits may be eligible)
  • Uncontrolled or significant cardiovascular disease
  • Known infection with HIV, HBV, or HCV. The following participants may be enrolled in this study (the Sponsor reserves the right to restrict enrollment of these participants):; Participants who are HIV-positive with undetectable HIV RNA and at least 3 months on antiretroviral therapy; Participants with a positive serologic test for HBV (i.e., positive HBcAb and negative HBsAg) and have a negative PCR test; Participants who are HCV-positive who have completed at least 1 month of highly effective antiviral therapy and have a negative PCR test
  • QT interval for heart rate using Fridericia's formula (QTcF) > 480 msec or history of additional risk factors for Torsades de Pointes
  • Active Grade ≥ 2 anorexia, nausea or vomiting, and/or signs of intestinal obstruction

Where in United States

  • Austin, TexasHospital not named in the registryTaking people
  • Dallas, TexasHospital not named in the registryTaking people
  • Denver, ColoradoHospital not named in the registryTaking people
  • Fairfax, VirginiaHospital not named in the registryTaking people
  • Greenville, South CarolinaHospital not named in the registryTaking people
  • Huntersville, North CarolinaHospital not named in the registryTaking people
  • Oklahoma City, OklahomaHospital not named in the registryTaking people
  • Orlando, FloridaHospital not named in the registryTaking people
  • San Antonio, TexasHospital not named in the registryTaking people
  • Sarasota, FloridaHospital not named in the registryTaking people

About the trial

What the trial wants to find out

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

The 8 groups in the trial

  • DL1 of DR-0202Treatment being tested

    Participants in this arm will receive DL1 milligrams of DR-0202 every 2 weeks until progression or withdrawal

    Treatment: DR-0202

  • DL2 of DR-0202Treatment being tested

    Participants in this arm will receive DL2 milligrams of DR-0202 every 2 weeks until progression or withdrawal

    Treatment: DR-0202

  • DL3 of DR-0202Treatment being tested

    Participants in this arm will receive DL3 milligrams of DR-0202 every 2 weeks until progression or withdrawal

    Treatment: DR-0202

  • DL4 of DR-0202Treatment being tested

    Participants in this arm will receive DL4 milligrams of DR-0202 every 2 weeks until progression or withdrawal

    Treatment: DR-0202

  • DL5 of DR-0202Treatment being tested

    Participants in this arm will receive DL5 milligrams of DR-0202 every 2 weeks until progression or withdrawal

    Treatment: DR-0202

  • DL6 of DR-0202Treatment being tested

    Participants in this arm will receive DL6 milligrams of DR-0202 every 2 weeks until progression or withdrawal

    Treatment: DR-0202

  • DL7 of DR-0202Treatment being tested

    Participants in this arm will receive DL7 milligrams of DR-0202 every 2 weeks until progression or withdrawal

    Treatment: DR-0202

  • DL8 of DR-0202Treatment being tested

    Participants in this arm will receive DL8 milligrams of DR-0202 every 2 weeks until progression or withdrawal

    Treatment: DR-0202

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Plain-language title
Tests DR-0202 in adults with advanced or returning solid tumor cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
7 January 2026